Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Director Kevin Tang Purchases 100,000 Shares

Key Points

• Aurinia Pharmaceuticals Director Kevin Tang purchased 100,000 shares at $11.34 each, valuing the transaction at $1,134,000, increasing his total ownership in the company.
• The stock price of Aurinia Pharmaceuticals rose 2.2%, reaching $11.70, with significant trading volume reported at over 3 million shares.
• Aurinia Pharmaceuticals recently reported earnings of $0.16 EPS, missing estimates by $0.01, while revenue exceeded expectations at $70.01 million.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) TSE: AUP Director Kevin Tang purchased 100,000 shares of Aurinia Pharmaceuticals stock in a transaction dated Monday, August 4th. The shares were acquired at an average cost of $11.34 per share, for a total transaction of $1,134,000.00. Following the completion of the transaction, the director owned 11,129,500 shares of the company's stock, valued at approximately $126,208,530. This represents a 0.91% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Kevin Tang also recently made the following trade(s):

• On Tuesday, August 5th, Kevin Tang purchased 200,000 shares of Aurinia Pharmaceuticals stock. The shares were acquired at an average cost of $11.68 per share, for a total transaction of $2,336,000.00.
• On Friday, August 1st, Kevin Tang purchased 1,000,000 shares of Aurinia Pharmaceuticals stock. The shares were acquired at an average cost of $10.12 per share, for a total transaction of $10,120,000.00.

Aurinia Pharmaceuticals Stock Performance

Shares of NASDAQ AUPH traded down $0.06 during mid-day trading on Friday, hitting $11.37. The stock had a trading volume of 2,496,968 shares, compared to its average volume of 2,572,066. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 5.23. The company has a 50 day moving average of $8.70 and a two-hundred day moving average of $8.26. Aurinia Pharmaceuticals Inc has a twelve month low of $5.29 and a twelve month high of $11.80. The firm has a market cap of $1.50 billion, a PE ratio of 26.44 and a beta of 1.23.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its earnings results on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.01). Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The firm had revenue of $70.01 million during the quarter, compared to analyst estimates of $64.27 million. Research analysts predict that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. purchased a new stake in Aurinia Pharmaceuticals in the fourth quarter valued at $27,000. Tower Research Capital LLC TRC boosted its holdings in Aurinia Pharmaceuticals by 368.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 2,635 shares during the last quarter. Vermillion & White Wealth Management Group LLC purchased a new stake in Aurinia Pharmaceuticals in the fourth quarter valued at $31,000. GAMMA Investing LLC boosted its stake in shares of Aurinia Pharmaceuticals by 56.1% during the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock worth $39,000 after acquiring an additional 1,744 shares in the last quarter. Finally, MAI Capital Management purchased a new stake in shares of Aurinia Pharmaceuticals during the 1st quarter worth about $39,000. 36.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on AUPH. HC Wainwright reaffirmed a "buy" rating and set a $17.00 price target on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th. Royal Bank Of Canada upped their price target on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an "outperform" rating in a research report on Friday, August 1st.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.